Screener
Axsome Therapeutics AXSM Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Operating lease liability, current portion | 628 | 434 |
| Contingent consideration, current | 11,150 | 10,012 |
| Short-term borrowings | 70,000 | 70,000 |
| Total current liabilities | 439,211 | 378,836 |
| Contingent consideration, non-current | 73,730 | 77,540 |
| Loan payable, long-term | 117,850 | 117,746 |
| Operating lease liability, long-term | 22,385 | 23,182 |
| Finance lease liability, long-term | 5,844 | 4,206 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's total current liabilities?
- Axsome Therapeutics (AXSM) reported total current liabilities of $439.21M in Q1 2026.
- How has Axsome Therapeutics's total current liabilities changed year-over-year?
- Axsome Therapeutics's total current liabilities increased by 80.1% year-over-year, from $243.91M to $439.21M.
- What is the long-term trend for Axsome Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Axsome Therapeutics's total current liabilities has grown at a 74.5% compound annual growth rate (CAGR), from $23.44M to $378.84M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Axsome Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude